Heh, I was watching it climb out of that dip again and wondered if I should jump in? I hesitated a bit and it quickly reached the previous peak of 350-400%. I thought there was no way it could go higher than that… boy was I wrong 
Trading has been halted countless times today.
I think there was some new cancer treatment research result behind it.
Yes, breast cancer treatment, with a completed 5-year follow-up study, in which the recurrence rate is 0, which is a strong result.
Edit: Oh, I guess it’s time for the dump:
Has anyone here looked into North American psychedelic stocks? Regulations there have recently eased, and apparently at least in Canada, palliative care patients are entitled to use them. The idea is that in the future, psychedelics could be used more generally as a form of treatment for mental health patients. Some psychedelic stocks I’ve been following for a while are, for example, Mind Medicine and Numinus Wellness. Both have risen hundreds of percent during the autumn. Mr. Wonderful, familiar to many, has at least started investing in the industry. I’ll have to see if I open a small “mushroom piggy bank” myself. 
There’s already a thread about these here. Interesting companies, especially MM, which has several different psychedelic-based drugs in the pipeline. Unfortunately, these have invariably been OTC (over-the-counter) stocks, and I didn’t take an initial position for this reason, before the real rocketing began. There’s enough of a cannabis hype feel to these increases that it’s worth being careful if you’re planning to jump in at current prices.
Heh, I wonder if they’ll be able to push the post-1:10 split value back to the pre-split value 
At this rate, it won’t be long until Nasse gets fired again and there’s another reverse split Luckily, I’d had enough of this one and took my money out last fall, manly swallowing a non-deductible -50% loss on OST. -50% is better than, say, -90%. Hopefully, not too many people fell for it earlier when, was it MS, updated the target price quite high 
Huh, glad I jumped off this train a couple of weeks ago before the reverse split at $0.45/share. At that point, I had a -43% loss, now it would be much bigger.
Moral of the story: jump off even with a hefty loss if your faith in the investment is gone or you don’t understand the investment target.
As classic a falling knife as it gets. Practically in a monthly downtrend since going public, even though it tried to bounce in early 2017. It bounced to 175 when it went public, and has been slipping and sliding ever since. A stock like this would require at least a weekly trend change to even consider a short swing trade. Big institutions emptied their pockets in early June, based on the volume bar.
Many bag holders are scooping up more shares into their portfolios on the verge of despair, trying to lower the average price to maintain some hope. I need to keep an eye out today for a volume climax drop; I could try to scalp some gains from that.
I checked this out in the summer because the story about a new antibiotic (resistance issues) seemed so good. However, in my investment strategy, it’s written in big red letters that I don’t touch these small pharmaceutical companies other than as a short trade. So, luckily, I didn’t play this card.
@Torniojaws, if I remember correctly, you’ve followed the company more closely. What’s behind the constant decline, and why hasn’t FDA approval been granted? You’d think a new, effective antibiotic would address a truly massive need.
Many bag holders are scooping up more shares into their portfolios on the brink of despair
I recognize myself, now at a nice -60% on the board and considering adding more today.
This is really strange and there must be something else behind it. The offering price was really well below the share price, but the offering only raises a trivial 15M. It seems really odd, as if they are trying to drive the share price down by all means possible.
Nordnet apparently doesn’t want this to be traded today, and the value shows as zero. A sign of things to come?
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
- Amended agreement encompasses enhanced manufacturing collaboration and regulatory support
- Accelerates milestone payments to Nabriva, including fourth quarter 2020 payment of $1 million
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the restructuring of its license agreement with Sinovant Sciences for XENLETA™ (lefamulin) in the greater China region. The restructured agreement provides for additional manufacturing collaboration and regulatory support [to be provided to Sinovant by Nabriva] that is expected to help expedite the delivery of XENLETA to patients in greater China. The restructured agreement accelerates components of the $5 million milestone payment to Nabriva that was previously payable upon regulatory approval of XENLETA in China, including a payment of $1 million in the fourth quarter of 2020.
In March 2018, Nabriva granted to Sinovant Sciences an exclusive license to develop and commercialize XENLETA (SNV001) in China. Under the original license agreement, Nabriva received a $5 million upfront payment and is eligible for up to approximately $90 million in additional payments tied to the successful completion of certain regulatory and commercial milestones related to XENLETA for community acquired bacterial pneumonia (CABP) in China. In addition, Nabriva will be eligible to receive low double-digit royalties on sales of XENLETA following regulatory approval in the greater China region. Sinovant Sciences is currently conducting a clinical trial of XENLETA in China.
Something like that was previously in the Pharmaceutical Industry thread. Could this have something to do with that offering?
I have that Nabriva stock and sold it like crazy when RS happened. Since then, Nordea hasn’t gotten their calculations in order in a week, and I couldn’t sell during the week as it kept dropping. The dividend calculator doesn’t seem to work. It’s the last US stock I have in Nordea, the rest are already in Degiro. Without Nordea’s reasonable fees, I would have switched providers a long time ago.
Nordean’s operations after the RS are an even worse process than ticker changes. I personally experienced the RS with a final slip in the summer and a simultaneous transfer to another stock exchange with the same stock. It was apparently 1.5 weeks out of play before they got it sorted out.
Tricky situations. Most often, however, one should break the mental block and sell the position. Or at least halve it. Of course, if one knows the company and products, the rise can well begin, but how far will that business then raise the share price? Often it’s better to sell and even buy back when there is evidence of a change in business.
Well, no need to think about moves when Nordnet doesn’t allow trading at all. So, the current stocks stay and we’ll forget about it. Maybe it’s better this way.
